A Phase 2 interventional study of Multivalent Group B streptococcus vaccine and Tetanus, diphtheria, and acellular pertussis vaccine in Group B Streptococcus Infections, sponsored by Pfizer. Completed at 12 sites in United States. Open to female participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-24.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This phase 2B, placebo-controlled, randomized, observer-blinded trial will evaluate the safety, tolerability, and immunogenicity of the investigational multivalent group B streptococcus vaccine administered concomitantly with Tdap in healthy nonpregnant women 18 through 49 years of age.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multivalent group B streptococcus vaccine and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
Biological: Multivalent Group B streptococcus vaccine · Biological: Tetanus, diphtheria, and acellular pertussis vaccine
Multivalent group B streptococcus vaccine and Placebo
Biological: Multivalent Group B streptococcus vaccine · Biological: Placebo
Placebo and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
Biological: Tetanus, diphtheria, and acellular pertussis vaccine · Biological: Placebo
Multivalent Group B streptococcus vaccine
Tetanus, diphtheria, and acellular pertussis vaccine
Also known as: Tdap
Saline control
Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination
Local reactions (redness, swelling, and pain at the injection site of the left arm) were recorded by participants in e-diary. Erythema/Redness and induration/swelling were measured and recorded in measuring device units (1 measuring device unit=0.5 centimeter \[cm\]). Grading: Grade 1/mild (greater than \[\>\] 2.0 to 5.0 cm), Grade 2/moderate (\>5.0 to 10.0 cm), Grade 3/severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as Grade 1/mild (did not interfere with activity), Grade2/moderate (interfered with activity), Grade 3/severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person.
Time frame: Day 1 (day of vaccination) to Day 7
Percentage of Participants Reporting Systemic Reactions Within 7 Days After Vaccination
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Nausea/vomiting was graded as: Grade 1/mild (1-2 times in 24 hours \[h\]), Grade 2/moderate: (\>2 times in 24h), Grade 3/severe (required intravenous hydration) and Grade 4 (ER visit/hospitalization for hypotensive shock). Diarrhea was graded as: Grade 1/mild (2-3 loose stools in 24h), Grade 2/moderate (4-5 loose stools in 24h), Grade 3/severe (6 or more loose stools in 24h) and Grade 4 (ER visit/hospitalization for severe diarrhea). Fatigue/tiredness, headache, chills, muscle pain and joint pain were graded as: Grade 1/mild (did not interfere with activity), Grade 2/moderate (some interference with activity), Grade 3/severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Grade 4 were classified by investigator or medically qualified person.
Time frame: Day 1 (day of vaccination) to Day 7
Percentage of Participants Reporting Adverse Events (AEs) Through 1 Month After Vaccination
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. In this outcome measure results excluded data for local reactions and systemic events.
Time frame: Day 1 (day of vaccination) through 1 Month post-vaccination
Percentage of Participants Reporting Medically Attended Adverse Events (MAEs) and Serious Adverse Events (SAEs) Through 6 Months After Vaccination
A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect; or that was considered as an important medical event.
Time frame: Day 1 (day of vaccination) through 6 Months post-vaccination
Percentage of Participants Achieving Anti-tetanus Toxoid (Anti-TTd) and Anti-diphtheria Toxoid (Anti-DTd) Antibody Concentration >=0.1 IU/mL at 1 Month After Vaccination: GBS6 + Tdap and Placebo + Tdap Groups
IU/mL stands for international units per milliliter.
Time frame: 1 Month after Vaccination (Day 1, day of vaccination)
Geometric Mean Concentration (GMC) of Anti-Pertussis Toxin (PT), Anti-Filamentous Hemagglutinin (FHA), and Anti-Pertactin (PRN) Antibodies; GMR of Anti-PT, Anti-FHA, and Anti-PRN for GBS6 + Tdap to Placebo + Tdap at 1 Month After Vaccination
GMCs of anti-PT, anti-FHA, and anti-PRN was reported as descriptive data for the GBS6 +Tdap and placebo + Tdap groups, along with associated 2-sided 95% confidence interval. GMR for anti-PT, anti-FHA and anti-PRN antibodies were estimated from the GBS6 + Tdap group to the placebo + Tdap group and reported as statistical data.
Time frame: 1 Month after Vaccination (Day 1, day of vaccination)
GMC of GBS Capsular Polysaccharide (CPS) Serotype-Specific Immunoglobulin G (IgG) Antibodies; GMR of GBS CPS Serotype-specific IgG Antibodies for GBS6 + Tdap to Placebo + Tdap at 1 Month After Vaccination
GBS CPS serotype-specific IgG GMCs (Ia, Ib, II, III, IV, V) were reported as descriptive data for the GBS6+Tdap and GBS6+placebo groups, along with associated 2-sided 95% confidence interval. GMR of GBS CPS serotype-specific IgG antibodies were estimated from the GBS6 + Tdap group to the placebo + Tdap group and reported as statistical data.
Time frame: 1 Month after Vaccination (Day 1, day of vaccination)
Healthy non-pregnant female participants aged 18-49 years, were randomized to receive multivalent group B streptococcus 6-valent polysaccharide conjugate vaccine (GBS6) and tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap), or GBS6 and placebo, or placebo and Tdap.
| Milestone | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap |
|---|---|---|---|
| Started | 103 | 99 | 104 |
| Vaccinated | 102 | 99 | 103 |
| Completed | 99 | 93 | 98 |
| Not completed | 4 | 6 | 6 |
| Withdrew: Lost to follow-up | 3 | 5 | 3 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 |
| Withdrew: Other | 0 | 0 | 1 |
Local reactions (redness, swelling, and pain at the injection site of the left arm) were recorded by participants in e-diary. Erythema/Redness and induration/swelling were measured and recorded in measuring device units (1 measuring device unit=0.5 centimeter \[cm\]). Grading: Grade 1/mild (greater than \[\>\] 2.0 to 5.0 cm), Grade 2/moderate (\>5.0 to 10.0 cm), Grade 3/severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as Grade 1/mild (did not interfere with activity), Grade2/moderate (interfered with activity), Grade 3/severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person.
| Percentage of participants | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap |
|---|---|---|---|
| Pain at injection site: Any | 39.2 (29.7 to 49.4) | 45.9 (35.8 to 56.3) | 33.0 (24.1 to 43.0) |
| Pain at injection site: Mild | 27.5 (19.1 to 37.2) | 35.7 (26.3 to 46.0) | 26.2 (18.0 to 35.8) |
| Pain at injection site: Moderate | 11.8 (6.2 to 19.6) | 9.2 (4.3 to 16.7) | 6.8 (2.8 to 13.5) |
| Pain at injection site: Severe | 0 (0.0 to 3.6) | 1.0 (0.0 to 5.6) | 0 (0.0 to 3.5) |
| Pain at injection site: Grade 4 | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Erythema/redness: Any | 7.8 (3.4 to 14.9) | 2.0 (0.2 to 7.2) | 0 (0.0 to 3.5) |
| Erythema/redness: Mild | 4.9 (1.6 to 11.1) | 1.0 (0.0 to 5.6) | 0 (0.0 to 3.5) |
| Erythema/redness: Moderate | 2.9 (0.6 to 8.4) | 1.0 (0.0 to 5.6) | 0 (0.0 to 3.5) |
| Erythema/redness: Severe | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Erythema/redness: Grade 4 | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Induration/swelling: Any | 3.9 (1.1 to 9.7) | 4.1 (1.1 to 10.1) | 1.9 (0.2 to 6.8) |
| Induration/swelling: Mild | 1.0 (0.0 to 5.3) | 2.0 (0.2 to 7.2) | 0 (0.0 to 3.5) |
| Induration/swelling: Moderate | 2.9 (0.6 to 8.4) | 2.0 (0.2 to 7.2) | 1.9 (0.2 to 6.8) |
| Induration/swelling: Severe | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Induration/swelling: Grade 4 | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Nausea/vomiting was graded as: Grade 1/mild (1-2 times in 24 hours \[h\]), Grade 2/moderate: (\>2 times in 24h), Grade 3/severe (required intravenous hydration) and Grade 4 (ER visit/hospitalization for hypotensive shock). Diarrhea was graded as: Grade 1/mild (2-3 loose stools in 24h), Grade 2/moderate (4-5 loose stools in 24h), Grade 3/severe (6 or more loose stools in 24h) and Grade 4 (ER visit/hospitalization for severe diarrhea). Fatigue/tiredness, headache, chills, muscle pain and joint pain were graded as: Grade 1/mild (did not interfere with activity), Grade 2/moderate (some interference with activity), Grade 3/severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Grade 4 were classified by investigator or medically qualified person.
| Percentage of participants | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap |
|---|---|---|---|
| Fever: >= 38.0°C | 1.0 (0.0 to 5.3) | 4.0 (1.1 to 10.1) | 2.9 (0.6 to 8.3) |
| Fever: 38.0°C to 38.4°C | 0 (0.0 to 3.6) | 2.0 (0.2 to 7.2) | 2.9 (0.6 to 8.3) |
| Fever: >38.4°C to 38.9°C | 1.0 (0.0 to 5.3) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 3.6) | 2.0 (0.2 to 7.2) | 0 (0.0 to 3.5) |
| Fever: >40.0°C | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Nausea/vomiting: Any | 14.7 (8.5 to 23.1) | 17.2 (10.4 to 26.3) | 14.6 (8.4 to 22.9) |
| Nausea/vomiting: Mild | 7.8 (3.4 to 14.9) | 12.1 (6.5 to 20.4) | 12.6 (6.9 to 20.6) |
| Nausea/vomiting: Moderate | 6.9 (2.8 to 13.6) | 5.1 (1.7 to 11.5) | 1.9 (0.2 to 6.8) |
| Nausea/vomiting: Severe | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Nausea/vomiting: Grade 4 | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Diarrhea: Any | 19.6 (12.4 to 28.6) | 16.2 (9.2 to 25.2) | 21.4 (13.9 to 30.5) |
| Diarrhea: Mild | 15.7 (9.2 to 24.2) | 11.1 (5.7 to 19.2) | 13.6 (7.6 to 21.8) |
| Diarrhea: Moderate | 3.9 (1.1 to 9.7) | 4.0 (1.1 to 10.1) | 7.8 (3.4 to 14.7) |
| Diarrhea: Severe | 0 (0.0 to 3.6) | 1.0 (0.0 to 5.6) | 0 (0.0 to 3.5) |
| Diarrhea: Grade 4 | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Headache: Any | 35.3 (26.1 to 45.4) | 48.5 (38.3 to 58.7) | 38.8 (29.4 to 48.9) |
| Headache: Mild | 23.5 (15.7 to 33.0) | 34.3 (25.1 to 44.6) | 26.2 (18.0 to 35.8) |
| Headache: Moderate | 10.8 (5.5 to 18.5) | 13.1 (7.2 to 21.4) | 12.6 (6.9 to 20.6) |
| Headache: Severe | 1.0 (0.0 to 5.3) | 1.0 (0.0 to 5.5) | 0 (0.0 to 3.5) |
| Headache: Grade 4 | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Fatigue/tiredness: Any | 51.0 (40.9 to 61.0) | 50.5 (40.7 to 61.3) | 46.6 (36.7 to 56.7) |
| Fatigue/tiredness: Mild | 29.4 (20.8 to 39.3) | 21.2 (13.8 to 30.9) | 19.4 (12.3 to 28.4) |
| Fatigue/tiredness: Moderate | 20.6 (13.2 to 29.7) | 24.2 (16.4 to 34.2) | 26.2 (18.0 to 35.8) |
| Fatigue/tiredness: Severe | 1.0 (0.0 to 5.3) | 5.1 (1.7 to 11.5) | 1.0 (0.0 to 5.3) |
| Fatigue/tiredness: Grade 4 | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Muscle pain: Any | 30.4 (21.7 to 40.3) | 24.2 (16.4 to 34.2) | 26.2 (18.0 to 35.8) |
| Muscle pain: Mild | 14.7 (8.5 to 23.1) | 13.1 (7.3 to 21.6) | 14.6 (8.4 to 22.9) |
| Muscle pain: Moderate | 15.7 (9.2 to 24.2) | 10.1 (5.0 to 18.0) | 11.7 (6.2 to 19.5) |
| Muscle pain: Severe | 0 (0.0 to 3.6) | 1.0 (0.0 to 5.6) | 0 (0.0 to 3.5) |
| Muscle pain: Grade 4 | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
| Joint pain: Any | 17.6 (10.8 to 26.4) | 15.2 (8.8 to 24.0) | 12.6 (6.9 to 20.6) |
| Joint pain: Mild | 9.8 (4.8 to 17.3) | 10.1 (5.0 to 18.0) | 5.8 (2.2 to 12.2) |
| Joint pain: Moderate | 7.8 (3.4 to 14.9) | 3.0 (0.6 to 8.7) | 6.8 (2.8 to 13.5) |
| Joint pain: Severe | 0 (0.0 to 3.6) | 2.0 (0.2 to 7.2) | 0 (0.0 to 3.5) |
| Joint pain: Grade 4 | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 0 (0.0 to 3.5) |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. In this outcome measure results excluded data for local reactions and systemic events.
| Percentage of participants | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap |
|---|---|---|---|
| Percentage of Participants Reporting Adverse Events (AEs) Through 1 Month After Vaccination | 5.9 (2.2 to 12.4) | 8.1 (3.6 to 15.3) | 3.9 (1.1 to 9.6) |
A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect; or that was considered as an important medical event.
| Percentage of participants | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap |
|---|---|---|---|
| MAEs | 4.9 (1.6 to 11.1) | 4.0 (1.1 to 10.0) | 6.8 (2.8 to 13.5) |
| SAEs | 0 (0.0 to 3.6) | 0 (0.0 to 3.7) | 1.0 (0.0 to 5.3) |
IU/mL stands for international units per milliliter.
| Percentage of participants | GBS6 + Tdap | Placebo + Tdap |
|---|---|---|
| Anti-TTd | 100.0 (96.3 to 100.0) | 100.0 (96.4 to 100.0) |
| Anti-DTd | 100.0 (96.3 to 100.0) | 100.0 (96.4 to 100.0) |
GMCs of anti-PT, anti-FHA, and anti-PRN was reported as descriptive data for the GBS6 +Tdap and placebo + Tdap groups, along with associated 2-sided 95% confidence interval. GMR for anti-PT, anti-FHA and anti-PRN antibodies were estimated from the GBS6 + Tdap group to the placebo + Tdap group and reported as statistical data.
| Endotoxin units per milliliter (EU/mL) | GBS6 + Tdap | Placebo + Tdap |
|---|---|---|
| GMC of Anti-PT antibodies | 17.975 (14.519 to 22.254) | 32.916 (26.641 to 40.668) |
| GMC of Anti-FHA antibodies | 108.377 (93.479 to 125.650) | 191.140 (161.964 to 225.571) |
| GMC of Anti-PRN antibodies | 158.887 (132.346 to 190.751) | 270.294 (222.691 to 328.072) |
GBS CPS serotype-specific IgG GMCs (Ia, Ib, II, III, IV, V) were reported as descriptive data for the GBS6+Tdap and GBS6+placebo groups, along with associated 2-sided 95% confidence interval. GMR of GBS CPS serotype-specific IgG antibodies were estimated from the GBS6 + Tdap group to the placebo + Tdap group and reported as statistical data.
| mcg/mL | GBS6 + Tdap | GBS6 + Placebo |
|---|---|---|
| Ia | 13.015 (7.095 to 23.874) | 14.616 (7.965 to 26.821) |
| Ib | 2.421 (1.322 to 4.431) | 2.106 (1.037 to 4.278) |
| II | 63.656 (40.279 to 100.600) | 61.709 (39.961 to 95.291) |
| III | 3.521 (2.107 to 5.885) | 5.547 (3.239 to 9.500) |
| IV | 6.065 (4.097 to 8.980) | 4.115 (2.746 to 6.167) |
| V | 1.307 (0.722 to 2.363) | 2.337 (1.209 to 4.517) |
Collected over Local reaction and systemic events (systematic assessment): up to 7 days post-vaccination; All-cause mortality, SAEs, MAEs (non-systematic assessment): up to 6 months post-vaccination; Other AEs (non-systematic assessment): up to 1-month post-vaccination [vaccination was on Day 1]. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GBS6 + Tdap | 0/102 (0%) | 0/102 (0%) | 81/102 (79.4%) |
| GBS6 + Placebo | 0/99 (0%) | 0/99 (0%) | 71/99 (71.7%) |
| Placebo + Tdap | 0/103 (0%) | 1/103 (1%) | 79/103 (76.7%) |
| Event | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap |
|---|---|---|---|
| Bile duct stoneHepatobiliary disorders | 0/102 | 0/99 | 1/103 |
| Event | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap |
|---|---|---|---|
| Fatigue (FATIGUE)General disorders | 52/102 | 50/99 | 48/103 |
| Headache (HEADACHE)Nervous system disorders | 36/102 | 48/99 | 40/103 |
| Injection site pain (PAIN)General disorders | 40/102 | 45/99 | 34/103 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 31/102 | 24/99 | 27/103 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 20/102 | 16/99 | 22/103 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 18/102 | 15/99 | 13/103 |
| Vomiting (NAUSEA/VOMITING)Gastrointestinal disorders | 15/102 | 17/99 | 15/103 |
| Injection site erythema (REDNESS)General disorders | 8/102 | 2/99 | 0/103 |
| Injection site swelling (SWELLING)General disorders | 4/102 | 4/99 | 2/103 |
| Pyrexia (FEVER)General disorders | 1/102 | 4/99 | 3/103 |
Safety set included all participants who received at least 1 dose of the study interventions and had at least 1 valid post dose safety assessment.
| Age, Continuous(Years) | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap | Total |
|---|---|---|---|---|
| Mean | 35.4 ± 8.54 | 34.8 ± 8.60 | 35.5 ± 8.59 | 35.3 ± 8.55 |
| Sex: Female, Male(Participants) | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap | Total |
|---|---|---|---|---|
| Female | 102 | 99 | 103 | 304 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap | Total |
|---|---|---|---|---|
| Hispanic or Latino | 8 | 12 | 16 | 36 |
| Not Hispanic or Latino | 93 | 86 | 86 | 265 |
| Unknown or Not Reported | 1 | 1 | 1 | 3 |
| Race (NIH/OMB)(Participants) | GBS6 + Tdap | GBS6 + Placebo | Placebo + Tdap | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 0 | 4 |
| Asian | 3 | 5 | 1 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 18 | 19 | 19 | 56 |
| White | 80 | 68 | 75 | 223 |
| More than one race | 0 | 4 | 4 | 8 |
| Unknown or Not Reported | 0 | 0 | 4 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Aug 2022 to primary completion in Apr 2023, 8 months.
Results were first posted in May 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.